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Abstract Coronary artery disease is the leading cause of
death worldwide. Many trials to date have investigated the
diagnostic accuracy of coronary computed tomography angi-
ography (CCTA) when compared to the gold standard diag-
nostic test, invasive coronary angiography. However, whether
the use of a non-invasive anatomical test, such as CCTA, can
translate into improved patient risk stratification, management
and outcome has yet to be established. The Scottish
COmputed Tomography of the HEART (SCOT-HEART) trial
sought to address these questions and determined whether
CCTA, when used in addition to standard care, could aid the
diagnosis, further investigation and treatment of patients re-
ferred to the cardiology clinic with suspected angina due to
coronary heart disease. In this trial, CCTA clarified the diag-
nosis of angina due to coronary heart disease in a quarter of
patients and this led to major alterations in treatment and man-
agement that appeared to reduce the risk of subsequent coro-
nary heart disease death or non-fatal myocardial infarction.
The SCOT-Heart trial has established that CCTA is a valuable
diagnostic test in patients with suspected angina pectoris due
to coronary heart disease and leads to greater clarity, more
focused appropriate treatments and better coronary heart dis-
ease outcomes.
Keywords CTcoronary angiography . Angina . Coronary
heart disease . Myocardial infarction . Outcomes
Introduction
Despite significant advances in detection and management,
atherosclerotic coronary artery disease remains a leading
cause of ill health and mortality throughout the world [1].
Invasive coronary angiography remains the gold standard for
the diagnosis of coronary artery disease, but is an invasive
investigation associated with a small risk of serious complica-
tions [2]. The adoption of an effective, safe, non-invasive
strategy to diagnose and risk stratify patients in order to im-
prove clinical outcomes is the goal of current diagnostic
approaches.
The evolution of coronary computed tomography an-
giography (CCTA) has seen improved temporal and spa-
tial resolution and has raised the promise of providing
such an accurate non-invasive anatomical evaluation of
the coronary arteries. More recently, questions have fo-
cused, not only on the diagnostic accuracy of CCTA,
but also its clinical application and value in improving
patient outcomes (Table 1).
The Scottish COmputed Tomography of the HEART
(SCOT-HEART) trial was designed as a multicenter
randomised controlled trial to assess systematically the
role of CCTA in the diagnosis, management and prog-
nosis of patients referred to the cardiology clinic with
recent onset stable chest pain. The main questions ad-
dressed by the SCOT-HEART trial included whether
CCTA could be of value when used alongside standard
care in improving not only diagnosis but also further
management and patient outcomes [12••].
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CCTA as a Diagnostic Tool
Diagnostic Accuracy
Chest pain remains an extremely frequent presentation and
clinical history alone is often inadequate at accurately diag-
nosing and risk stratifying patients with suspected angina sec-
ondary to coronary heart disease. A report by Sekhri et al.
investigated the outcome of patients referred with chest pain
to cardiology clinics and found that, whilst those patients di-
agnosed with angina had a greater risk of cardiovascular
events, patients diagnosed with non-cardiac chest pain
accounted for almost one third of cardiovascular-related
deaths over a median follow-up period of 2.5 years [13].
Patients who were misdiagnosed were more likely to be youn-
ger and describe atypical symptoms. This highlights the need
for improved diagnostic accuracy in this group of low- to
intermediate-risk patients and suggests that this population
may benefit most from a detailed anatomical non-invasive
investigation, such as CCTA.
The diagnostic accuracy of CCTA has been well demon-
strated in previous studies [14]. Initially, such studies predom-
inantly included high-risk patients, or small cohorts of patients
in single centres, leading to concerns about the lack of evi-
dence supporting the use of CCTA in patient groups with a
lower probability of coronary heart disease and thus its
generalisability in the real-world setting [15–17]. In the mul-
ticenter coronary artery evaluation using 64-rowmultidetector
computed tomography angiography (CORE 64) study, CCTA
demonstrated a negative predictive value of 83 % and positive
predictive value of 91 % when used in symptomatic patients
with suspected coronary heart disease and calcium scores of
Table 1 Summary of important CCTA studies to date
Primary aim First author/title
and year, reference
number
Patients
(n)
Population
characteristics
Disease prevalence
(% >50 % stenosis)
Major findings
Diagnostic accuracy
of CCTA compared
to invasive angiography
Budoff MJ et al.
(ACCURACY)
2008 [3]
230 Typical/atypical pain.
No known CAD
25 NPVof 99 % compared with
invasive angiography
Miller, J et al.
(CORE-64)
2008 [4]
291 Only patients with
CAC ≤600 included
in primary analysis
56 90 % PPVof CCTA
Lower NPVof 83 %
Meijboom et al.
2008 [5]
360 Acute and stable anginal
symptoms
68 99 % sensitivity and NPVof
97 % in detecting significant
stenosis. Specificity of 64 % [5].
Triage of patients from
Emergency Department
(accuracy in diagnosis
of ACS)
Hoffman et al.
(ROMICAT)
2009 [6]
368 Acute chest pain with
normal initial troponin
and ECG
18.5 100 % sensitivity and NPV for
diagnosis of ACS in absence
of CAD [6]
Goldstein et al.
(CT-STAT)
2011 [7]
699 Low-risk acute chest
pain presenting to ED
4 (>70 % stenosis)
10 (25–70 %
stenosis)
54 % reduction in time to diagnosis
compared with MPI, lower cost
of care and no difference in
adverse outcomes [7]
Prognostic Value of CCTA Puchner et al.
(ROMICATII)
2014 [8]
472 Acute chest pain.
Low-risk patients
10 Presence of high-risk plaques
independent predictor of ACS
(OR 8.9) [8]
Chow et al.
2010 [9]
2076 Various indications
(58 % chest pain)
30 CTA measures of CAD and TPS
have incremental prognostic
value over clinical predictors [9]
Hadamitzky M et al.
2013 [10]
1584 Suspected, but not
known CAD
20 Severity of CAD on CTA and TPS
predicted death or non-fatal MI
over standard clinical risk scores
during 5 years follow-up [10]
Assessing clinical
effectiveness of CCTA
in diagnosis, management
and outcomes.
Douglas P et al.
(PROMISE)
2015 [11••]
10,003 Symptomatic patients
referred for
investigation
11 CTA associated with fewer
invasive angiograms showing no
obstructive disease. Reduction in
CHD death/non-fatal MI at
12 months. No difference in
outcome at 25 months [11••]
Newby DE
et al.
(SCOTHEART)
2015 [12••]
4146 Recent onset chest
pain, suspected CHD
42 CTA clarified diagnosis of angina
secondary to CHD in 1 in 4
patients [12••].
OR odds ratio, MPI myocardial perfusion imaging, TPS total plaque score
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less than 600 [4]. In this trial population, there was a high
prevalence of coronary heart disease (56 % for ≥50% stenosis
on conventional coronary angiography), implying that CCTA
can provide robust diagnostic information in higher risk
groups. However, the primary analyses excluded patients with
calcium scores greater than 600 [4]. In a substudy of the
CORE-64 trial population, the diagnostic accuracy of CCTA
was also noted to be high in the evaluation of patients with
suspected acute coronary syndrome as well as stable coronary
heart disease [18]. Similarly, the ACCURACY study, con-
ducted by Budoff et al. in 2008, investigated the diagnostic
performance of 64-multidetector row CCTA in symptomatic
patients with suspected coronary heart disease who had been
referred for elective invasive coronary angiography [3]. The
results demonstrated that CCTA possessed a high sensitivity
for the detection of stenosis at both 50 and 70 % thresholds
with a negative predictive value of 99 %. In this study, whilst
the specificity of coronary heart disease obstruction detection
was 83%, the positive predictive value dropped to 48% in the
identification of severe stenosis [3].
From the existing evidence, it is discernible that CCTA
holds greatest value in the reliable exclusion of coronary ar-
tery disease, particularly in low- or intermediate-risk patients.
Additionally, its use aids the diagnosis of coronary heart dis-
ease by reliably detecting the presence of coronary atheroscle-
rosis. However, its reliability can falter in the accurate grading
of stenosis and has been especially impeded by the over esti-
mation of stenotic plaques, particularly in the presence of sig-
nificant coronary calcification (Fig. 1). This has led to concern
regarding the generalisability of CCTA as an effective diag-
nostic tool in the real-world population, particularly with re-
gard to the clinical diagnosis of angina due to the suspicion of
a significant incidence of false positives.
Real-World Diagnosis of Angina
The primary objective of the SCOTHEART trial was to inves-
tigate the role of CCTA in the clinical diagnosis of angina, in
order to test the generalisability of this non-invasive test in the
real-world setting. The trial was intentionally designed to
include a broad population of patients, truly reflective of those
presenting to the cardiology clinic with stable chest pain of
recent onset. Almost half of all eligible patients were recruited
to the study, including patients with high calcium scores, high
bodymass index and atrial fibrillation. A total number of 4146
patients were randomised (1:1) to standard care alone (includ-
ing cardiovascular risk assessment) or to standard care plus
coronary calcium score and CCTA. Randomisation used
minimisation to match for age, sex, BMI, diabetes, history
of coronary heart disease, atrial fibrillation and baseline diag-
nosis of angina due to coronary heart disease. At baseline,
cardiovascular risk was calculated using the ASSIGN score
[19]. Clinicians were asked to diagnose coronary heart disease
and angina secondary to coronary heart disease, as well as
documenting their level of confidence in the diagnosis both
at baseline and at 6 weeks follow-up. The study was powered
to recruit 2069 patients per group to detect an absolute change
of 4 % in the diagnosis of angina.
As opposed to comparing CCTA directly with functional
testing, the SCOT-HEART trial was designed to assess the
role of CCTA in addition to usual standard care, to investigate
the benefit of this anatomical investigation in clarifying the
diagnosis of angina secondary to coronary heart disease. In
fact, the majority of patients (85 %) underwent exercise ECG
prior to CCTA. The exercise ECG was abnormal in 15 % of
patients [12••]. When completing the baseline assessment, the
clinician diagnosed 47 % of patients as having coronary heart
disease and 36 % of patients as having angina secondary to
coronary heart disease. At baseline, only a small percentage of
patients had a history of coronary heart disease, but there was
a high prevalence of cardiovascular risk factors.
Consequently, there were a large number of patients receiving
preventativemedications, with over 40% of patients receiving
a statin and 48% an antiplatelet agent. Themean predicted 10-
year cardiovascular risk was 17 % [12••]. Nonetheless, the
majority of patients who underwent CCTA had either normal
coronary arteries (38 %) or non-obstructive disease (37 %).
Overall, diagnostic quality was obtained in the vast majority
of patients and excellent inter-observer and intra-observer var-
iability was documented in the diagnosis of both coronary
Fig. 1 Example of coronary
computed tomography
angiography (CCTA) image in a
55-year-old gentleman with a
calcium Agatston score of 1400
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heart disease and angina secondary to coronary heart disease
[20].
For a diagnostic test to be useful, it must increase the cli-
nician’s certainty of detecting or excluding a specific condi-
tion. At 6 weeks follow–up, the diagnosis of coronary heart
disease, as defined by the attending clinician’s report, was
reclassified in 27 % of patients assigned to CCTA in addition
to standard care, compared with only 1 % of patients assigned
to standard care alone. Similarly, the diagnosis of angina sec-
ondary to coronary heart disease changed in 23 % of patients
assigned to CCTA compared to 1 % assigned to standard care.
The use of CCTA doubled the certainty of diagnosing both
coronary heart disease and angina secondary to coronary heart
disease [12••].
In summary, the results of the SCOT-HEART trial demon-
strate CCTA provides a non-invasive test that can identify or
exclude coronary atherosclerosis and increase the certainty of
the clinical diagnosis of angina secondary to coronary heart
disease in patients presenting with recent onset stable chest
pain.
Invasive Coronary Angiography
Following previous evidence highlighting the reduced posi-
tive predictive value in assessing the severity of coronary ste-
nosis, there is a concern that CCTAwill increase the number
of invasive angiograms showing non-obstructive disease. In
the SCOT-HEART trial, whilst the use of CCTAwas associ-
ated with a small increase in early referrals, there was no
overall difference in the rates of invasive coronary angiogra-
phy. In patients where CCTA triggered a new request for in-
vasive coronary angiography, the majority (73 %) had evi-
dence of obstructive disease and over half (58 %) underwent
coronary revascularisation [12••]. Furthermore, 9 % of pa-
tients who proceeded underwent coronary artery bypass sur-
gery, highlighting the identification prognostically significant
coronary heart disease by CCTA. Indeed, long-term outcome
data could help provide evidence that such alterations in
downstream management driven by non-invasive imaging
confer prognostic benefit.
Another large randomised trial assessing the clinical use of
CCTA, the Prospective Multicenter Imaging Study for
Evaluation of Chest Pain (PROMISE) study, compared the
use of a diagnostic testing strategy using CCTAwith function-
al testing (stress ECG, stress ECHO or nuclear stress testing)
[11••]. The results revealed that there was a reduction in the
number of invasive angiograms showing no obstructive dis-
ease in the CTA arm compared with the functional testing arm
(3.4 vs 4.3 % respectively, p 0.02) [11••]. Overall, CCTA
appeared to reduce the rates of normal invasive coronary an-
giography at the same time as increasing the likelihood of
diagnosing important obstructive disease requiring coronary
revascularisation.
Safety
Historically, the use of CCTA has been associated with radia-
tion doses of up to 20 mSv and this has led to concern regard-
ing its widespread adoption as a first line investigation [21].
However, modern scanning techniques with the inclusion of
radiation-lowering applications such as prospective ECG gat-
ing and the use of iterative reconstruction have markedly
lowered this dose without compromising diagnostic accuracy
[21–23]. In the SCOTHEART trial, the median radiation dose
was 4.1 mSv, with greater than one third of this dose attribut-
able to the measurement of the coronary calcium score [12••].
The latter did not add any additional information to that ob-
tained by CCTA meaning that effective radiation doses are 2–
3 mSv for CCTA.
In the SCOTHEART and PROMISE trials, the number of
adverse reactions secondary to CCTAwas very low (2%), and
all of these were recorded as mild and self-limiting [2, 11••].
As a diagnostic tool, CCTA is therefore a safe, reliable and
reproducible test which can add valuable anatomical informa-
tion about the coronary arterial circulation. The clinical imple-
mentation of this tool in addition to exercise electrocardiogra-
phy provides a means whereby an accessible and cost-
effective functional assessment can be coupled with an accu-
rate anatomical test, clarifying the diagnosis of myocardial
ischaemia secondary to coronary heart disease and reducing
the need for further stress testing. By clarifying the diagnosis
of angina secondary to coronary heart disease, this allows
appropriate tailoring of subsequent management, including
focusing invasive angiography to those in whom this is nec-
essary. Similarly, such diagnostic clarification avoids the la-
belling and lifelong adherence to unnecessary medication in
those patients in whom coronary heart disease is excluded.
Evidence has concluded that a normal CCTA confers an ex-
cellent prognosis and extends a Bwarranty period^ of at least
7 years [24, 25].
CCTA as a Prognostic Tool
Following the acquisition of evidence supporting the diagnos-
tic accuracy and clinical use of CCTA in the detection of
coronary artery disease, and since the rapid development of
cardiovascular imaging, there has been a drive to examine the
impact of diagnostic imaging on both risk stratification and
clinical outcomes.
Risk Stratification by CCTA
Early studies examining the role of CCTA in accurate risk
stratification and prognosis were largely limited to single cen-
tres and small patient cohorts [26]. In order to refine this ev-
idence, the international multicenter CONFIRM (Coronary
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CT Angiography evaluation for Clinical outcomes) registry
was developed and has enrolled over 30,000 patients who
have undergone CCTA for evaluation of suspected coronary
heart disease [26]. When examining the use of CCTA in pa-
tients without chest pain, results from the CONFIRM registry
revealed that coronary artery calcium scoring and CCTA both
enhanced risk stratification for all-cause mortality and a com-
posite of all-cause mortality and non-fatal MI. However, the
added value of CCTA over a model based on standard risk
factors and CACS was negligible, suggesting this test could
not be justified for screening of an asymptomatic population
[27]. When asymptomatic patients were stratified by coronary
artery calcium score, CCTA added incremental prognostic
value over the Framingham Risk Score for the prediction of
mortality and non-fatal MI for asymptomatic individuals with
moderate coronary artery calcium scores (101–400), but not
lower (<100) or higher scores (>400) [28].
In contrast, for symptomatic patients with suspected coronary
heart disease, the use of CCTA measures of coronary heart dis-
ease improved discrimination of patients at risk of death or myo-
cardial infarction when added sequentially to traditional risk
models, clinical variables and coronary artery calcium score [29].
CCTA and Prognosis
In order for a diagnostic test to alter outcomes, the results must
be interpreted and clinical knowledge used to translate this
information into further treatment decisions, such as the initia-
tion and adherence to evidence-based medication. Therefore, it
is challenging for a diagnostic test to have a direct effect on
clinical outcomes. However, we have learned from the
SCOTHEART trial that the use of CCTA leads to large changes
in treatment decisions and these changes appeared to reduce the
subsequent risk (hazards ratio 0.62, p=0.0527) of coronary
heart disease death and non-fatal MI over a median follow up
period of 1.7 years. This appears to be attributable to changes in
preventative therapies and coronary revascularisation [12••].
Interestingly, the results of the PROMISE trial also revealed a
reduction in death and non-fatal MI in the CCTA group in a
pre-specified analysis over the initial 12-month follow up peri-
od (HR 0.66, p=0.049) [11••]. However, this benefit was not
apparent at the completion of follow-up.
In both the SCOTHEARTand PROMISE trials, the overall
absolute event rates were low, reflective of the fact that the
majority of patients had either normal coronary arteries or
mild coronary artery disease [2, 11••]. Further research is
therefore required with longer term follow-up in order to in-
vestigate more fully the effect of CCTA on clinical outcomes.
Patient-Centred Outcomes
In the SCOTHEART trial, patients’ symptoms were reassessed
at 6 weeks and there was no significant change in symptom
frequency or severity between the CCTA and standard care
groups. However, this was often the point at which the clinician
was fully informed regarding the outcome of CCTA in this arm
of the trial, and so could be considered too early to account for
subsequent alterations in diagnosis or management. Longer
follow-up is thus required to fully ascertain the effect of
CCTA on patient-centred outcomes [12••].
Future Perspectives
In addition to the accurate diagnosis of coronary atheroscle-
rosis, the evolution of CCTA has enabled the non-invasive
characterization of plaque morphology, which raises promise
for its future in accurate risk stratification and its potential to
reduce future major cardiac events. An advantage of CCTA
over invasive coronary angiography is the ability to visualise
the vessel wall, providing the potential to identify high-risk
features of coronary plaque despite a preserved vessel lumen
[30]. A meta-analysis analysing the ability of CCTA to pro-
vide quantitative measurements including vessel luminal area
and coronary plaque volume showed a sensitivity of 93 % and
specificity of 92 % when compared with intravascular ultra-
sound (IVUS) [31]. Furthermore, a meta-analysis demonstrat-
ed the ability of CCTA to differentiate low- from high-risk
patients in predicting the risk of future cardiac events [32].
Indeed, Motoyama et al. demonstrated that the presence of
high-risk plaques, as determined by CCTA, was an indepen-
dent predictor of subsequent acute coronary syndrome [33•].
The detection of plaque progression through serial CT coro-
nary angiography was an additional predictor of acute coro-
nary syndrome [33•].
In addition to the detection of high-risk plaque features on
CCTA, the evolution of approaches to combine this anatomi-
cal information with physiological measures of coronary
blood flow and perfusion holds promise for the future of
CCTA. Recent developments in the calculation of fractional
flow reserve noninvasively (FFRCT) have been highlighted in
three largemulticenter studies (NXT, DISCOVER-FLOWand
DeFACTO) which have compared the accuracy of FFRCT
with invasive FFR measurements [34–36]. A meta-analysis
of the DeFACTO, NXT and DISCOVER-FLOW trials con-
cluded that FFRCT has a pooled sensitivity similar to CCTA
(0.89 versus 0.89 at per-patient analysis; 0.83 versus 0.86 at
per-vessel analysis) but improves specificity in both a per-
vessel and per-patient analysis (0.71 versus 0.35 at per-
patient analysis; 0.78 versus 0.56 at per-vessel analysis)
[37]. The high negative predictive value of FFRCT has raised
promise for its potential to exclude ischaemia caused by inter-
mediate grade lesions, potentially avoiding unnecessary inva-
sive angiography [38]. Recently, the Prospective
LongitudinAl Trial of FFRCT: Outcome and Resource
Impacts (PLATFORM) study has investigated the clinical
use of FFRCT and the results revealed that CCTA with
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FFRCT did in fact lead to a marked reduction in the number of
invasive angiography showing no obstructive coronary artery
disease [39]. This was a non-randomised study and there was
no comparison with CTCA alone, and further study is there-
fore warranted.
Another technique which holds promise for the future po-
tential of CT to evaluate cardiac function and physiology is
the assessment of myocardial perfusion by CT. Studies com-
paring CT myocardial perfusion with alternative functional
imaging techniques including MRI and radionucleotide per-
fusion imaging have demonstrated sensitivities of 83–91 %
and specificities of 72–98 % for CT myocardial perfusion
imaging [40]. The multicenter combined coronary angiogra-
phy andmyocardial perfusion by computed tomography in the
identification of flow-limiting stenosis (CORE-320) study
combined CCTA and myocardial CT perfusion to investigate
the accuracy of CT perfusion compared to CCTA alone. The
results revealed that the combination of CCTA and CT perfu-
sion was accurate in identifying patients with flow-limiting
coronary artery disease, especially in patients with no known
coronary heart disease [41]. Furthermore, by stratifying the
CORE-320 population according to pre-test probability of
coronary artery disease, the results demonstrated that the use
of combined CT perfusion and CCTA added incremental di-
agnostic accuracy amongst patients with high calcium scores
[42]. Nonetheless, important limitations for CT perfusion im-
aging remain, including the impact of motion artefact and
beam hardening on image interpretation as well as concerns
regarding radiation dose [40]. With its evolution, this tech-
nique has the potential to develop as a valuable and accessible
clinical tool alongside CCTA.
Conclusions
CCTA continues to evolve as a rapidly developing imaging
modality and has the ability to clarify the diagnosis of angi-
na secondary to coronary heart disease. Results from the
SCOTHEART trial have highlighted that routine application
of CCTA, in addition to other clinical tools including exer-
cise ECG, helps guide patient management, select appropri-
ate treatments and appears to improve clinical outcomes in-
cluding myocardial infarction. The potential ability of CCTA
to evaluate and provide in depth information about plaque
morphology could lead to the identification of specific high-
risk characteristics within the vulnerable plaque, allowing
sophisticated and accurate risk stratification. Furthermore,
the evolution of these methods to combine physiological
evaluation with CCTA raise the promise for the adoption
of a single imaging platform to provide accurate diagnostic
information, guide management and ultimately improve car-
diovascular outcomes.
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